Mayo Clinic researchers have developed an innovative testing strategy for mesothelioma that could potentially increase the ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

On September 16, 2024, Immatics announced the proof-of-concept clinical data for the first candidate of its next-generation, ...

Novotech, the global full-service clinical CRO, has published a new report, Small Cell Lung Cancer: Global Clinical Trial ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

The report highlighted a number of barriers to these partnerships ... In August it was also announced that up to 18 new ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major ... According to ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition - - Continued to advance three clinical programs ...

A simplified imaging protocol using just five views still had good accuracy with a median AUROC of 0.85 and normalized mean ...

News stories about drink and needle spiking incidents can attract significant interest, but experts warn they can drive ...

For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...